Ignite Creation Date:
2025-12-26 @ 1:19 PM
Ignite Modification Date:
2025-12-29 @ 5:46 PM
Study NCT ID:
NCT00587106
Status:
COMPLETED
Last Update Posted:
2009-03-30
First Post:
2007-12-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Studies of Neurological Paraneoplastic Syndromes
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Study Overview
Official Title:
Studies of Neurological Paraneoplastic Syndromes
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is for patients with cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome.
Detailed Description:
Patients usually go to their doctors with neurological complaints and later find they have cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome. Paraneoplastic syndromes are rare conditions in which the immune system is involved in causing brain damage and fighting cancer.
Such patients with paraneoplastic neurologic degenerations(PNDs) may have autoantibodies, an antibody or protein the immune system creates that is directed against his or her own proteins. This study aims to better understand PNDS by:
* analyzing for autoantibodies in serum and cerebral spinal fluid
* analyzing for antigen specificity and for antigens in cancer tissue
* comparing PND autoantibodies with those in cancer patients but no PND
* comparing PND autoantibodies with those in PND patients but no cancer
* studying the immune performance of patients with PNDs
As this study is not a treatment study, tissues for this study will only come from procedures necessary for the patient's treatment.
Such patients with paraneoplastic neurologic degenerations(PNDs) may have autoantibodies, an antibody or protein the immune system creates that is directed against his or her own proteins. This study aims to better understand PNDS by:
* analyzing for autoantibodies in serum and cerebral spinal fluid
* analyzing for antigen specificity and for antigens in cancer tissue
* comparing PND autoantibodies with those in cancer patients but no PND
* comparing PND autoantibodies with those in PND patients but no cancer
* studying the immune performance of patients with PNDs
As this study is not a treatment study, tissues for this study will only come from procedures necessary for the patient's treatment.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: